"Amyloid immunotherapy has consistently shown an increase in brain volume loss – leading to concerns in the media and medical ...

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

A study conducted bà Cattolica in Rome and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS has uncovered a ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

While there is no cure for Alzheimer's disease, drug treatments aimed at slowing disease progression and alleviating symptoms ...

Scientists have created a game-changing 'Alzheimer's in a dish' model that allows for faster and more accurate testing of ...

Taking medications like blood pressure and lipid-lowering drugs for more than 5 years is associated with a lower incidence of ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, ...

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...

A future treatment for Alzheimer disease may involve a nasal spray. Researchers at Università Cattolica and Fondazione ...